Health Care Service Corporation granted coverage for Boston Scientific’s Intracept procedure, according to a news release shared Dec. 10 with Becker’s.
Intracept is a minimally invasive treatment for chronic vertebrogenic low back pain, and HCSC’s coverage went into effect on Dec. 1.
HCSC is one of the largest commercial health insurers in the U.S., and its policy covers more than 26 million people.
“This positive policy decision reflects the continued coverage momentum for Intracept that we’re seeing across commercial plans in the U.S.,” Mary Hailey, vice president of health economics and reimbursement, Neuromodulation at Boston Scientific, said in the release. “We remain committed to working with payers on the growing body of Intracept clinical evidence, with the goal of expanding access to a therapy that is proven to deliver significant and durable relief.”
